Autoimmune Bullous Diseases: Therapeutic Update - PubMed
6 hours ago
- #Dermatology
- #Clinical Trials
- #Autoimmune Diseases
- Autoimmune blistering diseases (AIBDs) are a group of disorders characterized by autoantibodies against skin and epithelial structural proteins.
- Recent RCTs focus on treatments for bullous pemphigoid, pemphigus vulgaris/foliaceus, and mucous membrane pemphigoid.
- Notable treatments include immunoadsorption, rilzabrutinib, efgartigimod for pemphigus, and dupilumab, benralizumab, mepolizumab, avdoralimab for bullous pemphigoid.
- Dupilumab's FDA approval for moderate/severe bullous pemphigoid marks a significant advancement.
- Despite progress, challenges remain in finding effective and safe therapies for AIBDs due to the rarity of these diseases and difficulties in trial designs.